Table 1.
Relationship between thrombotic types and clinical symptoms.
| Anatomical occurrence sites | No. of patients | Percentage (%) | Gastrointestinal bleeding | Refractory ascites | Severe liver dysfunction | Increase in thrombus |
|---|---|---|---|---|---|---|
| P | 23 | 23.5 | 22 | 3 | 0 | 2 |
| pb | 25 | 25.5 | 24 | 5 | 1 | 3 |
| pbm | 9 | 9.2 | 7 | 2 | 1 | 1 |
| pbs | 1 | 1.0 | 1 | 0 | 0 | 0 |
| pbms | 7 | 7.1 | 6 | 2 | 1 | 0 |
| pm | 9 | 9.2 | 8 | 1 | 1 | 1 |
| ps | 3 | 3.1 | 3 | 0 | 0 | 0 |
| pms | 1 | 1.0 | 1 | 0 | 0 | 0 |
| pc | 17 | 17.4 | 15 | 4 | 1 | 1 |
| pl | 3 | 3.1 | 2 | 1 | 0 | 0 |
| Total | 98 | 100 | 89 | 18 | 5 | 8 |
Severe liver dysfunction was defined as total bilirubin ≥ 50, ATP < 40%, and INR >1.5; or bilirubin >100. INR, international normalized ratio.
Increase in thrombus: an increase in the number of thrombus after treatment with other methods during a specific period (generally 2 weeks), or a gradual increase in the number of thrombus lasted for >1 week during the treatment.
MPV, main portal vein; pb, main portal vein + branch; pbm, main portal vein + branch + superior mesenteric vein; pbs, main portal vein + branch + splenic vein; pbms, main portal vein + branch + superior mesenteric vein + splenic vein; pm, main portal vein + superior mesenteric vein; ps, main portal vein + splenic vein; pms, main portal vein + superior mesenteric vein + splenic vein; pc, main portal vein + cavernous transformation; pl, main portal vein + liver transplantation.